About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Pfizer Has Agreed To Invest $90.5 Million In The Company To Speed Up The Development Of A Lyme Disease Vaccine.

As part of a joint effort with Valneva, Pfizer has agreed to invest $90.5 million ($95.25 million) in an 8.1% share in the company to accelerate the development of a Lyme disease vaccine.

Valneva VLA +26.98 percent (VLAN.France) will be purchased by the American pharmaceutical giant for €9.49 per share, according to a statement.

Since January, Valneva’s shares have lost about 62% of their value; but, on Monday, they gained 15.6% in European trade. Since the beginning of 2022, Pfizer (NYSE: PFE), which manufactures one of the most frequently used Covid-19 vaccines, has lost more than 21%. A Covid vaccination is also being developed by Valneva.

With Pfizer’s $2.00 percent investment, the French company plans to support its involvement in Lyme disease vaccine VLA15 Phase 3, which is expected to commence in the third quarter of this year.

Ticks carrying the Lyme disease bacterium may carry it to people. Pfizer has confirmed that VLA15 is the only vaccine candidate now in clinical development for the disease.

A partnership and license deal for VLA15, first announced in April 2020, was revised as part of the investment agreement between Pfizer and Valneva. Valneva has agreed to cover 40% of the remaining shared development expenditures, compared to 30% in the original agreement, which is a significant increase.

Pfizer will also pay tiered royalties of up to 22% to Valneva, as well as milestone payments of up to $100 million dependent on sales, according to the companies.

The post Pfizer Has Agreed To Invest $90.5 Million In The Company To Speed Up The Development Of A Lyme Disease Vaccine. appeared first on Best Stocks.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.